Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Rallied on positive clinical news, including FDA approval for combined treatment with Padcev, supporting continued Keytruda revenue growth, positive mid-stage data for Winrevair, and a US$700 million funding agreement with Blackstone Life Sciences for sac-TMT.
— Antipodes Global Value Fund
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Merck & Co., Inc.
More institutional theses from Antipodes Global Value Fund
The stock's recent underperformance over AI disruption fears creates an attractive entry point for this dominant online travel agency. Its deep supply-side...
A pending merger with its largest competitor offers significant cost synergies, expanded R&D capabilities, and scale. The company is...
This human resources platform is a structural growth compounder leveraging Japan's secular labor shortages and rising job mobility. Its core platform...